Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Yang Xu, Jia Yin, Jinlan Pan, Chunxiao Wu, Qinrong Wang, Hong Yao, Depei Wu, Suning Chen & Aining Sun. (2013) A BCR–JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. Leukemia & Lymphoma 54:10, pages 2322-2324.
Read now
Read now
Svetlana Angelova, Sylva Spassova, Stavri Toshkov & Velizar Shivarov. (2011) Chromosomal translocation t(9;22)(p24;q11) appears to be recurrently associated with myeloid malignancy with aggressive course. Leukemia & Lymphoma 52:9, pages 1809-1810.
Read now
Read now
Sylvia Hoeller, Christoph Walz, Andreas Reiter, Stephan Dirnhofer & Alexandar Tzankov. (2011) PCM1–JAK2-fusion: a potential treatment target in myelodysplastic–myeloproliferative and other hemato-lymphoid neoplasms. Expert Opinion on Therapeutic Targets 15:1, pages 53-62.
Read now
Read now
Yuejiao Zhong, Baoan Chen, Jifeng Feng, Lu Cheng, Yufeng Li, Jun Qian, Jiahua Ding, Feng Gao, Guohua Xia, Ningna Chen & Zuhong Lu. (2010) The associations of Janus kinase-2 (JAK2) A830G polymorphism and the treatment outcomes in patients with acute myeloid leukemia. Leukemia & Lymphoma 51:6, pages 1115-1120.
Read now
Read now
Stephen T Oh & Jason Gotlib. (2010) JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Review of Hematology 3:3, pages 323-337.
Read now
Read now
Lilian Varricchio, Annalisa Mancini & Anna Rita Migliaccio. (2009) Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Review of Hematology 2:3, pages 315-334.
Read now
Read now
Alessandro M Vannucchi, Paola Guglielmelli, Lisa Pieri, Elisabetta Antonioli & Alberto Bosi. (2009) Treatment options for essential thrombocythemia and polycythemia vera. Expert Review of Hematology 2:1, pages 41-55.
Read now
Read now
Ayalew Tefferi. (2009) JAK2V617F: more than a clonal marker?. Leukemia & Lymphoma 50:2, pages 154-155.
Read now
Read now
Ayalew Tefferi. (2008) Epigenetic alterations and anti-epigenetic therapy in myelofibrosis. Leukemia & Lymphoma 49:12, pages 2231-2232.
Read now
Read now
Ayalew Tefferi. (2008) Idiopathic erythrocytosis: a non-entity?. Leukemia & Lymphoma 49:9, pages 1649-1650.
Read now
Read now
Toshinori Kondo, Nanako Okuno, Hiromu Naruse, Mitsuyo Kishimoto, Taizo Tasaka, Takayuki Tsujioka, Akihito Matsuoka, Takashi Sugihara, Yumi Tohyama & Kaoru Tohyama. (2008) Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm. Leukemia & Lymphoma 49:9, pages 1784-1791.
Read now
Read now
Ayalew Tefferi. (2008) Is chronic myelomonocytic leukemia more akin to myelodysplastic or myeloproliferative neoplasms and does it matter?. Leukemia & Lymphoma 49:7, pages 1225-1227.
Read now
Read now
Articles from other publishers (52)
Yanhong Ni, Jun T. Low, John Silke & Lorraine A. O’Reilly. (2022) Digesting the Role of JAK-STAT and Cytokine Signaling in Oral and Gastric Cancers. Frontiers in Immunology 13.
Crossref
Crossref
Ayman Qasrawi & Ranjana Arora. (2021) Molecular Profile of BCR-ABL1 Negative Myeloproliferative Neoplasms and Its Impact on Prognosis and Management. Advances in Molecular Pathology 4, pages 65-79.
Crossref
Crossref
Qianqian Yin, Longyun Wang, Haiyang Yu, Daquan Chen, Wenwei Zhu & Changgang Sun. (2021) Pharmacological Effects of Polyphenol Phytochemicals on the JAK-STAT Signaling Pathway. Frontiers in Pharmacology 12.
Crossref
Crossref
Ana Azevedo, Susana Silva & José Rueff. 2019. Tyrosine Kinases as Druggable Targets in Cancer. Tyrosine Kinases as Druggable Targets in Cancer.
Xiangkun Wang, Xiwen Liao, Tingdong Yu, Yizhen Gong, Linbo Zhang, Jianlu Huang, Chengkun Yang, Chuangye Han, Long Yu, Guangzhi Zhu, Wei Qin, Zhengqian Liu, Xin Zhou, Junqi Liu, Quanfa Han & Tao Peng. (2019) Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma. International Journal of Oncology.
Crossref
Crossref
Barbara J. Bain, David M. Clark & Bridget S. Wilkins. 2019. Bone Marrow Pathology. Bone Marrow Pathology
267
345
.
Rishab Ramapriyan, Mauricio S. Caetano, Hampartsoum B. Barsoumian, Ana Carolina P. Mafra, Erika Pereira Zambalde, Hari Menon, Efrosini Tsouko, James W. Welsh & Maria Angelica Cortez. (2019) Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacology & Therapeutics 195, pages 162-171.
Crossref
Crossref
Kodappully S. Siveen, Kirti S. Prabhu, Iman W. Achkar, Shilpa Kuttikrishnan, Sunitha Shyam, Abdul Q. Khan, Maysaloun Merhi, Said Dermime & Shahab Uddin. (2018) Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products. Molecular Cancer 17:1.
Crossref
Crossref
Yan‑Bo Nie, Meng Sun, Colin He, Man‑Kai Ju, Fu‑Ling Zhou, San‑Yun Wu, Yi Zhou, Li Liu, Hui Shen, Ting‑Ting Huang, Pan Liu, Ying Xu, Liang Shao & Xue‑Lan Zuo. (2018) ASXL1 mutations in Chinese patients with essential thrombocythemia. Experimental and Therapeutic Medicine.
Crossref
Crossref
Myungmi LeeInmoo Rhee. (2017) Cytokine Signaling in Tumor Progression. Immune Network 17:4, pages 214.
Crossref
Crossref
Arthur ZimmermannArthur Zimmermann. 2017. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract
1427
1453
.
Yan Chen, Fang Fang, Yang Hu, Qian Liu, Dingfang Bu, Mei Tan, Liusong Wu & Ping Zhu. (2016) The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms. PLOS ONE 11:4, pages e0154183.
Crossref
Crossref
Arthur ZimmermannArthur Zimmermann. 2016. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract. Tumors and Tumor-Like Lesions of the Hepatobiliary Tract
1
27
.
Bulent Kantarcioglu, Isik Kaygusuz-Atagunduz, Ant Uzay, Tayfur Toptas, Tulin Firatli Tuglular & Mahmut Bayik. (2015) Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature. International Journal of Hematology 102:3, pages 383-387.
Crossref
Crossref
A Agarwal, R J MacKenzie, C A Eide, M A Davare, K Watanabe-Smith, C E Tognon, S Mongoue-Tchokote, B Park, R M Braziel, J W Tyner & B J Druker. (2014) Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia. Oncogene 34:23, pages 2991-2999.
Crossref
Crossref
Jon D. van der Walt. (2015) An update on BCR-ABL1-negative myeloproliferative neoplasms. Diagnostic Histopathology 21:5, pages 190-197.
Crossref
Crossref
John J. O'SheaDaniella M. SchwartzAlejandro V. VillarinoMassimo GadinaIain B. McInnesArian Laurence. (2015) The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. Annual Review of Medicine 66:1, pages 311-328.
Crossref
Crossref
Johanna Mondesir, Pierre Sujobert, Mark A Murakami, Marie-Anne Hospital, Didier Bouscary & Jerome Tamburini. (2014) Use of signaling pathways as therapeutic targets for blood cancer. International Journal of Hematologic Oncology 3:4, pages 275-288.
Crossref
Crossref
Kristin Kunze, Ulrike Gamerdinger, Jacqueline Leßig-Owlanj, Marina Sorokina, Alexander Brobeil, Mehmet Kemal Tur, Wolfgang Blau, Alexander Burchardt, Andreas Käbisch, Georg Schliesser, Michael Kiehl, Andreas Rosenwald, Mathias Rummel, Friedrich Grimminger, Torsten Hain, Trinad Chakraborty, Andreas Bräuninger & Stefan Gattenlöhner. (2014) Detection of an activated JAK3 variant and a Xq26.3 microdeletion causing loss of PHF6 and miR-424 expression in myelodysplastic syndromes by combined targeted next generation sequencing and SNP array analysis. Pathology - Research and Practice 210:6, pages 369-376.
Crossref
Crossref
Shinji Hirata, Naoya Takayama, Ryoko Jono-Ohnishi, Hiroshi Endo, Sou Nakamura, Takeaki Dohda, Masanori Nishi, Yuhei Hamazaki, Ei-ichi Ishii, Shin Kaneko, Makoto Otsu, Hiromitsu Nakauchi, Shinji Kunishima & Koji Eto. (2013) Congenital amegakaryocytic thrombocytopenia iPS cells exhibit defective MPL-mediated signaling. Journal of Clinical Investigation 123:9, pages 3802-3814.
Crossref
Crossref
Larissa V. Furtado, Helmut C. Weigelin, Kojo S.J. Elenitoba-Johnson & Bryan L. Betz. (2013) A Multiplexed Fragment Analysis-Based Assay for Detection of JAK2 Exon 12 Mutations. The Journal of Molecular Diagnostics 15:5, pages 592-599.
Crossref
Crossref
Julio Roberto Cáceres-Cortés. (2012) Blastic Leukaemias (AML): A Biologist’s View. Cell Biochemistry and Biophysics 66:1, pages 13-22.
Crossref
Crossref
Ashwani K. Singal, Patrick S. Kamath & Ayalew Tefferi. (2013) Mesenteric Venous Thrombosis. Mayo Clinic Proceedings 88:3, pages 285-294.
Crossref
Crossref
Ahmet Burak Toros, Serkan Gokcay, Guven Cetin, Muhlis Cem Ar, Yesim Karagoz & Besir Kesici. (2013) Portal Hypertension and Myeloproliferative Neoplasms: A Relationship Revealed. ISRN Hematology 2013, pages 1-5.
Crossref
Crossref
T. Seiler & M. Dreyling. (2012) Knochenmarkhistologie aus klinischer SichtBone marrow histology from the clinical point of view. Der Pathologe 33:6, pages 490-495.
Crossref
Crossref
Amy E. Schmidt. (2012) Pathology Consultation on Myeloproliferative Neoplasms. American Journal of Clinical Pathology 138:1, pages 12-19.
Crossref
Crossref
Alireza Eghtedar, Srdan Verstovsek, Zeev Estrov, Jan Burger, Jorge Cortes, Carol Bivins, Stefan Faderl, Alessandra Ferrajoli, Gautam Borthakur, Solly George, Peggy A. Scherle, Robert C. Newton, Hagop M. Kantarjian & Farhad Ravandi. (2012) Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 119:20, pages 4614-4618.
Crossref
Crossref
Tai-Sung Lee, Hagop Kantarjian, Wanlong Ma, Chen-Hsiung Yeh, Francis Giles & Maher Albitar. (2011) Effects of Clinically Relevant MPL Mutations in the Transmembrane Domain Revealed at the Atomic Level through Computational Modeling. PLoS ONE 6:8, pages e23396.
Crossref
Crossref
Anthony D. William, Angeline C.-H. Lee, Stéphanie Blanchard, Anders Poulsen, Ee Ling Teo, Harish Nagaraj, Evelyn Tan, Dizhong Chen, Meredith Williams, Eric T. Sun, Kee Chuan Goh, Wai Chung Ong, Siok Kun Goh, Stefan Hart, Ramesh Jayaraman, Mohammed Khalid Pasha, Kantharaj Ethirajulu, Jeanette M. Wood & Brian W. Dymock. (2011) Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma. Journal of Medicinal Chemistry 54:13, pages 4638-4658.
Crossref
Crossref
Michael Campoli & Soldano Ferrone. (2011) HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Seminars in Immunopathology 33:4, pages 321-334.
Crossref
Crossref
Erik Vakil & Ayalew Tefferi. (2011) BCR-ABL1?Negative Myeloproliferative Neoplasms: A Review of Molecular Biology, Diagnosis, and Treatment. Clinical Lymphoma Myeloma and Leukemia 11, pages S37-S45.
Crossref
Crossref
Rodrigo Lopes da Silva, Patricia Ribeiro, Alexandra Lourenço, Susana Costa Santos, Margarida Santos, Isabel Costa & Aida Botelho de Sousa. (2011) What Is the Role of JAK2<sup>V617F</sup> Mutation in Leukemic Transformation of Myeloproliferative Neoplasms?. Laboratory Hematology 17:1, pages 12-16.
Crossref
Crossref
Robert B. Lorsbach. 2011. Diagnostic Pediatric Hematopathology. Diagnostic Pediatric Hematopathology
217
244
.
Stephen T. Oh. (2010) When the brakes are lost: LNK dysfunction in mice, men, and myeloproliferative neoplasms. Therapeutic Advances in Hematology 2:1, pages 11-19.
Crossref
Crossref
David R. Czuchlewski, David S. Viswanatha & Richard S. Larson. 2011. Henry's Clinical Diagnosis and Management by Laboratory Methods. Henry's Clinical Diagnosis and Management by Laboratory Methods
1415
1440
.
James Huang & Richard D. Press. 2011. Essentials of Anatomic Pathology. Essentials of Anatomic Pathology
489
513
.
François W Paradis, Raynald Simard & Daniel Gaudet. (2010) Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology. BMC Medical Genetics 11:1.
Crossref
Crossref
Barbara Denys, Hakim El Housni, Friedel Nollet, Bruno Verhasselt & Jan Philippé. (2010) A Real-Time Polymerase Chain Reaction Assay for Rapid, Sensitive, and Specific Quantification of the JAK2V617F Mutation Using a Locked Nucleic Acid-Modified Oligonucleotide. The Journal of Molecular Diagnostics 12:4, pages 512-519.
Crossref
Crossref
M M Patnaik, T L Lasho, C M Finke, N Gangat, D Caramazza, S G Holtan, A Pardanani, R A Knudson, R P Ketterling, D Chen, J D Hoyer, C A Hanson & A Tefferi. (2010) WHO-defined ‘myelodysplastic syndrome with isolated del(5q)’ in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 24:7, pages 1283-1289.
Crossref
Crossref
Meredith A. Lakey, Animesh Pardanani, James D. Hoyer, Phuong L. Nguyen, Terra L. Lasho, Ayalew Tefferi & Curtis A. Hanson. (2010)
Bone Marrow Morphologic Features in Polycythemia Vera With
JAK2
Exon 12 Mutations
. American Journal of Clinical Pathology 133:6, pages 942-948.
Crossref
Crossref
David J. Matthews & Mary E. Gerritsen. 2010. Targeting Protein Kinases for Cancer Therapy. Targeting Protein Kinases for Cancer Therapy
215
264
.
Vesna Spasovski, Natasa Tosic, Tatjana Kostic, Sonja Pavlovic & Milica Colovic. (2010) JAK2-V617F mutation in patients with myeloproliferative neoplasms: Association with FLT3-ITD mutation. Srpski arhiv za celokupno lekarstvo 138:9-10, pages 614-618.
Crossref
Crossref
Li Song & Christian Schindler. 2010. Handbook of Cell Signaling. Handbook of Cell Signaling
2041
2048
.
Barbara J. Bain, David M. Clark & Bridget S. Wilkins. 2009. Bone Marrow Pathology. Bone Marrow Pathology
239
299
.
Justyna Kwapisz, Ewa Żekanowska & Joanna Jasiniewska. (2009) Decreased serum prohepcidin concentration in patients with polycythemia vera. Journal of Zhejiang University SCIENCE B 10:11, pages 791-795.
Crossref
Crossref
Anna D. Panani. (2009) Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: Clinical implications. Cancer Letters 284:1, pages 7-14.
Crossref
Crossref
Christopher J. Burns, David G. Bourke, Laura Andrau, Xianyong Bu, Susan A. Charman, Andrew C. Donohue, Emmanuelle Fantino, Michelle Farrugia, John T. Feutrill, Max Joffe, Marcel R. Kling, Margarita Kurek, Tracy L. Nero, Thao Nguyen, James T. Palmer, Ian Phillips, David M. Shackleford, Harrison Sikanyika, Michelle Styles, Stephen Su, Herbert Treutlein, Jun Zeng & Andrew F. Wilks. (2009) Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorganic & Medicinal Chemistry Letters 19:20, pages 5887-5892.
Crossref
Crossref
Giovanni BarosiGunnar BirgegardGuido FinazziMartin GriesshammerClaire HarrisonHans Carl HasselbalchJean-Jacques KiladjianEva LengfelderMary Frances McMullinFrancesco PassamontiJohn T. ReillyAlessandro M. Vannucchi & Tiziano Barbui. (2009) Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood 113:20, pages 4829-4833.
Crossref
Crossref
Adam M. Boruchov. (2009) Thrombocytopenia in Myelodysplastic Syndromes and Myelofibrosis. Seminars in Hematology 46, pages S37-S43.
Crossref
Crossref
V. Martn, J. Romn Gmez & A. Torres Gmez. (2008) S?ndromes mieloproliferativos: concepto y etiopatogenia. Clasificaci?n. Cl?nica. Criterios diagn?sticos. Estrategias terap?uticas. Medicine - Programa de Formaci?n M?dica Continuada Acreditado 10:21, pages 1409-1418.
Crossref
Crossref
Christian Schindler & Courtney Plumlee. (2008) Inteferons pen the JAK–STAT pathway. Seminars in Cell & Developmental Biology 19:4, pages 311-318.
Crossref
Crossref
B. Dupriez, J.-L. Demory, M.-C. Le Bousse-Kerdiles, S. Giraudier, C. Bilhou-Nabera, J.-F. Abgrall & J. Rey. (2008) Myélofibrose primitive. EMC - Hématologie 3:4, pages 1-14.
Crossref
Crossref